Campylobacter jejuni is a natural commensal of the avian intestinal tract. However, this 25 bacterium is also the leading cause of acute bacterial diarrhea worldwide and implicated in 26 development of Guillain-Barré syndrome. Like many bacterial pathogens, C. jejuni assembles 27 complex surface structures that interface with the surrounding environment and are involved in 
INTRODUCTION 47
Campylobacter jejuni is a major cause of bacterial diarrhea worldwide (1). Infection with 48 this pathogen results in significant acute illness as well as serious life-threatening consequences 49 such as Guillain-Barré syndrome (2). Like many bacterial pathogens, C. jejuni assembles 50 complex surface structures critical for long-term commensal colonization of avian host as well as 51 pathogenesis in humans. Two major surface structures, the glycolipid lipooligosaccharide (LOS) 52 and flagella, both important for pathogenesis, are often targets for modification and/or phase 53 variation, providing the bacteria with antigenic diversity and adaptability in inhospitable 54 environments. For example, variation of surface-exposed LOS results in a form of molecular 55 mimicry between bacterial surface and host peripheral nerve gangliosides, implicating them in 56 post-infectious neuropathies (2, 3). Another example is post-translational modification of 57 membrane and surface exposed proteins targeted by the C. jejuni Pse and Pgl family of proteins 58 responsible for O-and N-linked glycosylation, respectively. O-linked glycosylation of the 59 flagellar filament proteins, FlaA/B, is thought to provide antigenic diversity but the role N-linked 60 glycosylation plays in cellular processes is undetermined (4-6). Considering the importance of 61 LOS in host-pathogen interactions, a requirement for flagellar locomotion in many pathogens 62 and the unknown cellular processes influenced by N-linked glycosylation, the role played by C. 63 jejuni surface-modification systems in its pathogenesis warrants further investigation. 64 detection by the host toll-like receptor 4-myeloid differentiation factor 2 (TLR4-MD2) innate 70 immune receptor, which is found on leukocytes and epithelial surfaces (7, 8) . Recently, EptC 71 (Cj0256) was found to catalyze the addition of a phosphoethanolamine (pEtN) residue to variety 72 of periplasmic targets, lipid A, the flagellar rod protein FlgG at residue Thr 75 , and the terminal 73 sugar of N-linked heptasaccharides attached to several periplasmic proteins (9-11). Decoration 74 of C. jejuni lipid A phosphate groups with pEtN residues (Fig. 1B) , provided resistance to 75 polymyxin B (PMB), a polypeptide whose mechanism of killing is thought to mimic that of 76 CAMPs (i.e. defensins) (12) . Modification of FlgG with pEtN was shown to be required for 77 efficient flagella production and motility (9). However, no phenotype has been attributed to 78 pEtN modification on N-linked heptasaccharides. 79 LOS purified from C. jejuni shows reduced human (h)TLR4-MD2 activation when 80 compared to LPS purified from E. coli (13). These differences have been attributed to an 81 increased number of amide linked acyl chains at the 3-and 3′-positions of C. jejuni lipid A ( (m/z range of 600 -2800), followed by acquisition of MS/MS spectra for the three most 137 abundant ions from the full mass scan. Another set of MS/MS spectra were collected for the 138 three most abundant ions detected in the MS/MS scans. All CID-MS events were acquired using 139 a collisional energy setting of 1.25 V and an activation time of 30 ms. All solvents were HPLC 140 grade and purchased from Fisher Scientific (Pittsburgh, PA) with the exception of HPLC grade 141 10% NH 4 OH in H 2 O which was purchased from Sigma Aldrich (St. Louis, MO). 142
Determination of minimum inhibitory concentrations (MIC). For MIC determination 143
in liquid medium, the Hancock Laboratory Microtiter Broth Dilution Method was used and 144 modified as needed (21). C. jejuni strains were grown overnight in MH broth using standard 145 growth conditions. The overnight cultures were inoculated into 96-well microtiter plates at a 146 starting A 600 of 0.05, in a total volume of 100 μl standard C. jejuni growing medium, 147 supplemented with select concentration of cationic antimicrobial peptides (CAMP). The 96-well 148
plates were incubated at 37°C in a microaerobic atmosphere (5% O 2 , 10% CO 2 , and 85% N 2 ) 149 with constant shaking and A 600 of each well determined using a Synergy-Mx monochromator 150 based multi-mode microplate reader at 24 hours. Each experiment was repeated in triplicate. A 151 positive growth control containing no CAMP and a negative control containing no bacteria was 152 performed with every replicate. The MIC was taken as the lowest concentration of CAMP that 153 reduced growth (A 600 ) by more than 50% when compared to the positive growth control. The 154 following CAMPs were purchased and used in the MIC experiment: polymyxin B (Sigma), 155 human β defensin-2 (Phoenix Pharm), human cathelicidin LL-37 (Anaspec), histatin-5 P-113 156 (Sigma), and chicken gallinacin-6 (Biomatik). All peptides were stored according toToll-like receptor (TLR) signaling assay. For TLR4 and TLR2, human epithelial 159 kidney (HEK) 293 cells stably co-transfected with murine (m) or human (h) TLR4, m or hMD2, 160 and m or hCD14 (denoted as HEK-m/hTLR4) or hTLR2 and hCD14 (denoted as HEK-hTLR2) 161 were purchased from InvivoGen. All cell lines stably express secreted embryonic alkaline 162 phosphatase (SEAP) under the control of a promoter inducible by NF-κB and activator protein 1 163 (AP-1). Thus, stimulation of m/hTLR4-MD2 or hTLR2 will result in an amount of extracellular 164 SEAP in the supernatant that is proportional to the level of NF-κB induction. All cell lines are 165 commerically available from InvivoGen and are put through rigorous quality control and 166 validation to ensure that extracellular SEAP does not influence TLR4-MD2 activation or the 167 LOS structure. The cell lines were maintained in standard Dulbecco's modified Eagle's medium 168 (DMEM) with 10% heat-inactivated fetal bovine serum (FBS) (Gibco) supplemented with 4.5 169 g/L glucose, 2 mM L-glutamine, 50 U/mL penicillin, 50 μg/ml streptomycin and 1X HEK-Blue 170 selection (InvivoGen) in a 5% saturated CO 2 atmosphere at 37°C. 171
The induction of TLR signaling in HEK-m/hTLR4 and HEK-hTLR2 cell lines was 172 assessed by measuring SEAP activity using QUANTI-Blue TM colorimetric assay (InvivoGen). 173
The assay was performed according to manufacturer's protocols. Briefly, cells were seeded in a 174 96-well plate in triplicate (2.5 X 10 4 cells/well for HEK-m/hTLR4 and 5 X 10 4 cells/well for 175 HEK-hTLR2) in the presence or absence of 10-fold dilutions of purified LPS or bacterial cells 176 grown using standard conditions. Additionally, for whole cell experiments, cells were pelleted, 177 washed in PBS and inoculated into each well based on A 600 . Colony forming units (CFU) were 178 confirmed by plating serial dilutions on MH agar. The antibiotic erythromycin (50 μg/ml) was 179 included to prevent bacterial growth during incubation. importance to all commensal and pathogenic bacteria for survival in a host. In order to persist 276 within the digestive tract of chickens and survive the transition to a human GI environment, C. 277 jejuni must be resistant to CAMP found in both environments. Previous work from our lab 278 demonstrated that C. jejuni was highly resistant to polymyxin B (PMB), a polypeptide whose 279 mechanism of killing is thought to mimic that of CAMPs (i.e. defensins), with a minimal 280 inhibitory concentration (MIC) of wild type strains around ~18.0 μg/ml (9). Furthermore, we 281 demonstrated that addition of pEtN to the lipid A component of LOS by EptC was a mechanism 282 used by C. jejuni to resist the antimicrobial activity of PMB (9). However, it was not determined 283 if modification of LOS with pEtN by EptC actually provided resistance to relevant CAMPs 284 found in the human and avian GI tract. 285
For this study we chose a number of peptides found throughout the human and avian GI 286 tract including: (i) the human cathelicidin LL-37 produced by both leukocytes and epithelial 287 cells, (ii) human β-defensin 2 (HBD-2) found throughout the GI tract, (iii) P-113, a fragment of 288 human histatin 5 found within the oral cavity, and (iv) the chicken gallinacin 6 (Gal-6), a β6-289 defensin produced in the digestive tract of chickens (29, 30) . To determine the MICs, a standard 290 microtiter broth dilution method was utilized. As expected, C. jejuni 81-176 wild type was 291
highly resistant to all CAMPs tested (Table 2 ). In contrast, the eptC mutant showed a significant 292 decrease in its MIC (2.4-to 23-fold) to all human and avian CAMPs examined (Table 2) . 293 CAMP resistance was restored to wild type levels in the complemented eptC, eptC + strain (Table  294 2). Previous MICs were determined using Polymyxin B Etest® strips (Biomérieux) on agar 295
plates. The PMB MIC using the microtiter broth dilution method was lower than previous 296 on November 12, 2017 by guest http://iai.asm.org/ Downloaded from determinates using the Etest strips but the fold change when comparing wild type and the eptC 297 mutants was similar (~ 20-fold decrease), validating our results. These findings confirm that 298 modification of surface structures with pEtN by EptC is essential for resistance to CAMPs found 299 in the human and avian host. 300
Phosphoethanolamine addition to C. jejuni LOS by EptC results in attenuated 301
human TLR4-MD2 activation and differential recognition by murine TLR4-MD2. The 302 ability of LPS/LOS from a variety of organisms to activate hTLR4-MD2 has been extensively 303 studied. It is well documented that Gram-negative bacterial pathogens can alter the basic hexa-304 acylated bis-phosphorylated lipid A structure, like that found in E. coli K-12 ( The Toll-activation profiles of intact LOS were examined using samples purified using 316 the control of an NF-κB-inducible promoter allowing for easy detection of hTLR activation 320 using a colorimetric assay. When compared to LOS from wild type C. jejuni, LOS from the eptC 321 mutant showed a significant decrease in hTLR4-MD2 activation, requiring 100-fold more LOS 322 to reach maximal activation (Fig 4A) . hTLR4-MD2 activation by LOS prepared from the eptC, 323 eptC + complemented strain was identical to wild-type 81-176 (Fig. 4A) . These findings were 324 confirmed using whole cells. When compared to wild-type C. jejuni or the eptC, eptC + 325 complemented strain, the eptC mutant cells showed a significant decrease in hTLR4-MD2 326 activation (Fig. 4B) . Titration curves for whole cell experiments were performed and revealed 327 results similar to those for purified LOS (data not shown). For all experiments, LPS from R. 328 sphaeroides, a known hTLR4-MD2 antagonist (35), and E. coli were used as negative and 329 positive control for activation of hTLR4-MD2, respectively (Fig. 4A) . 330
The obvious progression of this research was to determine if pEtN modification of 331 substrates in C. jejuni are required for colonization of various hosts. For C. jejuni, a murine 332 model of infection has been established to investigate colonization of a mammalian host. 333
However, it is well documented in structural and experimental studies that murine (m)TLR4-334 MD2 displays differential recognition of LPS when compared to the activation profiles of 335 hTLR4-MD2 (15, 16). This presents a problem for attempting to determine the role TLR4-MD2 336 activation plays in virulence using a murine host. For this reason, we used purified LOS from 337 select C. jejuni strains to determine the mTLR4-MD2 recognition profile of pEtN-modified LOS. 338
Briefly, mTLR4-MD2 activity was monitored using HEK-293 cells stably transfected with 339 mTLR4-MD2-CD14 and quantified using an identical SEAP reporter method described above. 340 Surprisingly, when compared to wild type 81-176, LOS from the eptC mutant showed a 341 significant increase in mTLR4-MD2 activation (Fig. 5A) , requiring 100 fold less LOS for 342 on November 12, 2017 by guest http://iai.asm.org/ Downloaded from significant activation (1 ng/ml for wild type versus 0.01 ng/ml for eptC mutants). mTLR4-MD2 343 activation by LOS prepared from the eptC, eptC + complemented strain was identical to that of 344 wild type (Fig. 5A) . Again, these results were confirmed using whole cells, where purified LOS 345 was replaced with 10 8 CFU of C. jejuni (Fig. 5B) . For all experiments, endotoxin-free water and 346
LPS from E. coli were used as negative and positive controls for activation of mTLR4-MD2, 347 respectively (Fig. 5A) . LPS from R. sphaeroides is a known mTLR4-MD2 agonist and therefore 348 was used as a negative control (15). The ability mTLR4-MD2 to recognize a wide range of lipid 349
A substrates (i.e. penta-and tetra-acylated lipid A) when compared to hTLR4-MD2 is well 350 documented in the literature (15, 16) but increased recognition of pEtN-modified LOS was 351
unexpected. Considering the important role these molecules play during infection and the 352 reliance on murine host as a model for human infection, investigation of both h and mTLR4-353

MD2 are necessary. 354
The human Toll-like receptor 2 (hTLR2), known to recognize several conserved bacterial 355 structures including lipoteichoic acid and lipoproteins, has also been shown to recognize atypical 356 and heavily modified forms of LPS (36, 37). However, the ability of aberrant forms of LPS to 357 activate hTLR2 is controversial in the literature. Some of these discrepancies may arise because 358 of contaminating lipoproteins in LPS preparations. We felt it important to determine if pEtN-359 modified LOS from C. jejuni was able to activate hTLR2. Activation of hTLR2 was monitored 360 using HEK-293 cells stably transfected with hTLR2 and quantified using an identical SEAP 361 reporter method described above. No significant activation of hTLR2 was seen in LOS prepared 362 from all C. jejuni strains (Supplemental Fig 4) . For each experiment Pam3CSK4, a synthetic 363 lipopeptide and LPS from E. coli were used as positive and negative controls for activation of 364 on November 12, 2017 by guest http://iai.asm.org/ Downloaded from hTLR2 ( Supplemental Fig. 4) . Identical results were seen for activation of murine TLR2 (data 365 not shown). 366
Phosphoethanolamine modifications by EptC in C. jejuni are required for efficient 367 host colonization. To date, nothing is known regarding participation of C. jejuni LOS 368 modifications in host colonization. Presumably, the addition of pEtN to LOS by EptC provides 369 an advantage through resistance to CAMPs encountered in the host environment and attenuated 370 hTLR4-MD2 activation. Moreover, the reduction in motility in EptC mutants most likely would 371 translate into reduced colonization, as motility and flagellum production are required for 372 colonization of a host (22, 38). Considering our current and past findings, we felt it was 373 important to proceed with an in-vivo animal study to determine the role played by EptC in host 374
colonization. 375
To examine the ability of select C. jejuni strains to colonize a mammalian host, we used 376 the BALB/cByJ intestinal colonization model previously shown to identify colonization 377 differences between wild type and colonization-defective mutant strains (39, 40). Briefly, C. 378 jejuni 81-176 wild type, eptC and eptC, eptC + strains were administered by oral gavage to 379 BALB/cByJ mice (Jackson Laboratory) at a dose of 1 x 10 9 cfu. After 7 and 14 days, C. jejuni 380 shed in fecal pellets was enumerated on agar plates and reported as CFU per gram of fecal 381 material. The eptC-deficient mutant showed a significant decrease in colonization when 382 compared to wild type at both 7 (Fig. 6A ) and 14-days (Fig. 6B) To determine whether the murine colonization defect of the eptC mutant also occurred in 389 an avian host, the ability of select C. jejuni 81-176 strains to colonize the ceca of chicks after oral 390 inoculation was determined as previously described (22). Briefly, one-day old chicks were 391 orally inoculated with approximately 1 x 10 2 CFU of select C. jejuni strains. At seven days post-392 infection, chicks were sacrificed and the cecal contents were recovered and plated to determine 393 CFU per gram of cecal contents. The eptC-deficient mutant showed a 28-fold decrease in 394 colonization when compared to wild type (p < 0.05) (Fig. 7) . This colonization defect was 395 restored to wild type levels in the complemented strain, eptC, eptC + (Fig. 8) .
Chicks colonized 396
with EptC-deficient strains show greatly reduced commensal capacity suggesting an important 397 role for a pEtN-modified surface in the establishment of a C. jejuni-chicken commensal 398 recognition by TLR4-MD2 and the inability to colonize a murine host (17). C. jejuni LOS shows 440 limited potential to activate hTLR4-MD2 when compared to LPS purified from E. coli (Fig. 4A) . 441
This has been attributed, in part, to additional amide-linked acyl chains incorporated into the 442 lipid A of C. jejuni (Fig. 1B) (14) . Here we show that the addition of pEtN to LOS contributes to 443 an increase in hTLR4-MD2 activation. This finding agrees with a previous report that found a 444 positive correlation between hTLR4-MD2 activation and the number of phosphoryl substituents 445 The exact reason for decreased colonization in both a murine and avian model is difficult 460 to determine due to the number of targets modified with pEtN by EptC. Moreover, the number 461 of phenotypes influenced by the activity of EptC (i.e. CAMP resistance, motility and TLR4-MD2 462 modulation) limits our ability to properly pinpoint the exact cause of decreased colonization. For 463 example, motility and flagella production are required for colonization of murine and avian hosts 464 by C. jejuni (22, 48) . Furthermore, loss of CAMP resistance in C. jejuni strains resulting from 465
LOS core truncations also resulted in a reduction in colonization (18). EptC-deficient strains 466
show a reduction in motility and impaired flagella production as well as loss of CAMP 467 resistance, which likely act in concert to influence reduced colonization rates. A role for 468 increased hTLR4-MD2 activation by pEtN-modified LOS in the colonization of a host is even 469 more complicated due to the differential (i.e. decreased) activation of mTLR4-MD2. Given that 470 all C. jejuni strains we have examined produce pEtN-modified lipid A (9), the need for resistance 471 to CAMP is most likely of greater importance than increased detection by hTLR4-MD2 within LOS from the eptC mutant showed a significant decrease in hTLR4-MD2 activation, requiring 533 100 fold more LOS to reach maximal activation, 100 ng/ml for wild type versus 10,000 ng/ml for 534 eptC. hTLR4-MD2 activation by LOS prepared from the eptC, eptC + complemented strain was 535 identical to that of wild type (A). These results were confirmed using whole cells, where 536 purified LOS was replaced with C. jejuni cells (1 x 10 8 ). When compared to C. jejuni wild type 537 or eptC, eptC + strains, the eptC mutant cells showed a significant decrease in hTLR4-MD2 538 activation (B). Titration curves for whole cell experiments were performed and revealed results 539 similar to those for purified LOS (data not shown). For all experiments, LPS from R. 540 sphaeroides and E. coli were used as negative and positive controls for activation of hTLR4-541 MD2, respectively (A). Where appropriate, an asterisk was used to indicate significance (p ≤ 542 0.001). Statistical comparisons of mean activation were made between wild type and select 543 mutants LOS/whole cells. Data for this figure was generated from three experimental replicates 544 of a single biological replicate. However, all results agreed between at least two biological 545 LOS from the eptC mutant showed a significant increase in mTLR4-MD2 activation, requiring 555 100 fold less LOS for significant activation when compared to wild type, 1 ng/ml for wild type 556 versus 0.01 ng/ml for eptC. mTLR4-MD2 activation by LOS prepared from the eptC, eptC + 557 complemented strain was identical to that of wild type (A). These result were confirmed using 558 whole cells, where purified LOS was replace with C. jejuni cells (1 x 10 8 ). When compared to 559 C. jejuni wild type or eptC, eptC + strains, the eptC mutant cells showed a significant increase in 560 mTLR4-MD2 activation (B). Titration curves for whole cell experiments were performed and 561 revealed results similar to those for purified LOS (data not shown). For all experiments, media 562 and LPS from E. coli were used as negative and positive controls for activation of mTLR4-MD2, 563 respectively (A). Unlike hTLR4-MD2, LPS from R. sphaeroides is a known mTLR4-MD2 564 agonist and was not used as a negative control. Where appropriate, an asterisk was used to 565 indicate significance (p ≤ 0.001). Statistical comparisons of mean activation were made between 566 wild type and select mutants LOS/whole cells. Data for this figure was generated from three 567 experimental replicates of a single biological replicate. However, all results agreed between at 568 least two biological replicates. 
